Antiplatelet therapy

Hospital Medicine

Volumn 61, Issue 1, 2000, Pages 15-23

  Gershlick, A H ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PURINE P2 RECEPTOR; THROMBIN RECEPTOR;

CLASSIFICATION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBIN; THROMBOSIS;

EID: 0033630411     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2000.61.1.1267     Document Type: Article

References (26)

1. Al-Khadra AS. Salem DN. Rand WM et al (1992) Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cunliol 20: 419-25
2. Anonymous (1998a) Randomised placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stcnting with use of platelet glycoproteinIIB/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIs Inhibitor for Stentine. Lancet 352: 87-92
3. Anonymous (1998b) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatidc in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Intcgrilin Therapy. N Engl J Med 339: 436-43
4. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatclct therapy - I; prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1308: 81-106
5. Bachmann F. Savcic M. Hauen J et al (1996) Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 17: 263 (abstr)
6. Balsano F, Rizzon P, Violi F et al (1990) Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 82: 17-26
7. Baron JH, Aggrawal R, Ezekowitz MD, Azrin A, de Bono DP, Oershlick AH (1997) Adsorption and clution of c7E3 Fab from polymer coated stents in-vitro. Am J Cardiol 80: 37S
8. Beeb HG, Dawson DL. Cutler BS et al (1999) A new pharmacological treatment for intermittent claudication: results of a randomised multicenter clinical trial. Arch Intern Med 159: 2014-50
9. Bertrand M. Legrand V. Boland J et al (1996) Full anticoagulation versus ticlodipine plus aspirin after stem implantation: the FANTASTIC Trial. Circulation 94(8): 1-68
10. Brouwer MA, Bohncke JR, Veen G et al (1995) Adverse long-term effects of reocclusion after coronary thrombolysis. JAm Coll Cardiol 26: 1440-4
11. CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel vs aspirin in patients at risk of ischacmic events (CARRIE). Lancet 348: 1329-39
12. CAPTURE Study (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429-35
13. The EPILOG Investigators (1997) Platelet glyeoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336: 1689-96
14. The ERASER Investigators (1999) Acute platelet inhibition with abciximab does not reduce in-stent restenosis. The ERASER Study. Circulation 100: 799-806
15. Gent M, Blakely JA, Easton JD et al (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet i: 1215-20
16. Mass WK. Easton JD, Adams HP et al (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321: 501-1
17. Lincoff AM, Califf RM, Anderson KM et al (1997) Evidence for prevention of death and myocardial infarction with platelet membrane glyeoprotein Ilb/IIla receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. J Am Coll Cardiol 30: 149-56
18. Maresta A, Balducelli M, Cantini L et al (1994) Trapidil, a platelet derived growth factor inhibitor antagonist reduces restenosis after percutaneous transluminal angioplasty. Results of a randomised double blind clinical trial. Circulation 90: 2710-15
19. Nyman I, Larsson H, Wallentin L (1992) Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet 340: 497-501
20. Park SW, Lee CW, Kirn HS et al (1999) Comparison of cilostazol versus ticlodipinc treatment after stent implantation. Am J Cardiol 84: 511 -14
21. Prism Study Investigators (1998) Inhibition of the platelet glyeoprotein llb/llla receptor with Tirofiban in unstable angina and non-Q wave infarction. N Engl J Med 338: 1488-98
22. The Ridogrel v.v Aspirin Patency Trial (RAPT) (1994) Randomized trial of ridogrel, an endoperoxide receptor antagonist, v.v aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89: 588-95
23. Roux S. Christeller S, Ludin E (1992) Effects of aspirin on reocclusion and recurrent ischaemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19: 671-7
24. Schomig A, Neuman FJ, Kastrati A et al (1996) A randomised comparison of antiplatelet therapy after the placement of coronary stents. A' Engl J Med 334: 1084-9
25. Tcheng JE (1996) Glyeoprotein lib/Ilia receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 78: 35-40
26. Tcheng JE (1997) Impact of eptifibatide on early ischémie events in acute ischémie coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol 80: 21B-28B